ATOS - Atossa Genetics Inc Stock Price, Fair Value and News

$0.74+0.04 (+5.71%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ATOS Price Action

Last 7 days

-5.1%

Last 30 days

-13.9%

Last 90 days

-3.9%

Trailing 12 Months

-39.8%

ATOS RSI Chart

ATOS Valuation

Market Cap

95.6M

Price/Earnings (Trailing)

-3.17

Price/Sales (Trailing)

1.3K

EV/EBITDA

-1.45

Price/Free Cashflow

-3.64

ATOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ATOS Fundamentals

ATOS Revenue

Revenue (TTM)

84.6K

ATOS Earnings

Earnings (TTM)

-30.2M

Earnings Growth (Yr)

-20.22%

Earnings Growth (Qtr)

-3.19%

ATOS Profitability

Operating Margin

1752.83%

EBT Margin

-35657.74%

Return on Equity

-60.62%

Return on Assets

-52.02%

Free Cashflow Yield

-27.45%

ATOS Investor Care

Shares Dilution (1Y)

2.68%

Diluted EPS (TTM)

-0.23

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2015	0	0	0	0
2014	474.0K	157.8K	84.6K	0
2013	609.8K	712.8K	683.8K	632.6K
2012	0	0	0	481.8K
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

CEO	Dr. Steven C. Quay FCAP, M.D., Ph.D.
WEBSITE	https://atossatherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	11

Atossa Genetics Inc Frequently Asked Questions

What is the ticker symbol for Atossa Genetics Inc? What does ATOS stand for in stocks?

ATOS is the stock ticker symbol of Atossa Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atossa Genetics Inc (ATOS)?

As of Wed Dec 03 2025, market cap of Atossa Genetics Inc is 95.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATOS stock?

You can check ATOS's fair value in chart for subscribers.

Is Atossa Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether ATOS is over valued or under valued. Whether Atossa Genetics Inc is cheap or expensive depends on the assumptions which impact Atossa Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATOS.

What is Atossa Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ATOS's PE ratio (Price to Earnings) is -3.17 and Price to Sales (PS) ratio is 1.25 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATOS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Atossa Genetics Inc's stock?

In the past 10 years, Atossa Genetics Inc has provided -0.376 (multiply by 100 for percentage) rate of return.